Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) CEO Raza Bokhari tells Proactive the group has submitted an Investigational New Drug (IND) application to the FDA for the use of its lead candidate FSD-201, or anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA), to treat coronavirus patients. Bokhari says hopefully before the end of 2020, the group will initiate a Phase 2 trial to treat hospitalized coronavirus patients.
FSD Pharma Analysts report Brookline Capital Markets Report can be found here : https://www.docdroid.net/j08NxtN/fsd-pdf
If You have not yet done due diligence on RED Light Holland Check it out !!!!
Will be a strong branded truffle company with Russell Peters Backing, Bruce linton is the cherry on top.
Todd also knows a bunch of other famous people too.
Lets do this $TRIP / $TRUFF
https://www.newsfilecorp.com/release/62997/Red-Light-Holland-Announces-Arrangement-to-Launch-Sale-of-Psychedelic-Truffle-Microdosing-Packs-in-the-Netherlands
Red Light Holland Announces Arrangement to Launch Sale of Psychedelic Truffle Microdosing Packs in the Netherlands
Toronto, Ontario--(Newsfile Corp. - September 2, 2020) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) ("Red Light Holland" or the "Company"), an Ontario-based corporation positioning itself to engage in the production, growth and sale of its brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has solidified its arrangement with McSmart (as defined by the listing statement) for the launch of its previously announced Microdosing Packs through three Smart Shops operated by McSmart. The Microdosing Packs are anticipated to become available for purchase to consumers in the Netherlands before the end of September 2020, at the following Smart Shop locations: (i) two Tatanka locations, and (ii) the Headshop. In addition, the Microdosing Packs are also expected to become available for purchase in the Netherlands on Tatanka's website at www.tatanka.nl.
"All of us at Red Light Holland are very excited as our Microdosing Packs are so close to being on shelves and available for online purchases. We are still anticipating our premiere product launch, with our newly coined phrase "iMicrodose," happening later this month, and working so closely with McSmart is something we are truly appreciative of," said Todd Shapiro, Chief Executive Officer and Director of the Company.
Magic truffles, which are sold in their natural, raw and unprocessed form, need to be refrigerated. As such, two of the Smart Shops are also expected to feature Red Light Holland-branded fridges to house the magic truffles and display their iMicrodose packs in a clever and unique way. The Microdosing Packs have a shelf-life of approximately 3 months.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2017/62997_redlight_550.jpg
Red Light Holland Microdosing Packs
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/62997_redlight.jpg
About Red Light Holland Corp.
The Company is an Ontario-based corporation positioning itself to engage in the production, growth and sale of its brand of magic truffles to the legal, recreational market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws. The Company's brand of magic truffles are expected to be sold in the Netherlands through existing Smart Shops as well as its e-commerce platform, and are expected to be initially made available in the form of its previously announced Microdosing Packs.
News release
Gratomic Aims to Become a Cleaner Source of Graphite for North American Consumers.
Red Light Holland Announces Arrangement to Launch Sale of Psychedelic Truffle Microdosing Packs in the Netherlands
$TRIP #Psychedelics
News Release
FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19
FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19
- The study is expected to be conducted at 25-30 hospitals in North America -
August 31, 2020 02:30 AM Eastern Daylight Time
TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) an Investigational New Drug Application (IND) for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the “FSD201 COVID-19 Trial”). Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. As previously announced, FSD Pharma is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.
COVID-19 Trial Design
The FSD201 COVID-19 Trial will be a randomized, controlled, double-blind, multicenter study, conducted at 25-30 sites in North America to assess the efficacy and safety of FSD201 dosed at 600mg or 1200mg twice-daily, together with standard of care ("SOC") compared to SOC alone in hospitalized patients with documented COVID-19 disease.
Issuance of Share-Based Compensation and Early Warning Disclosure for Dr. Raza Bokhari, Executive Co-Chairman & CEO
Further to our news release dated July 31, 2020, the Board of Directors has authorized the issuance of an additional 369,255 class B subordinate voting shares ("Class B Shares") to certain of the Company's directors, officers, employees and consultants as share-based compensation.
As will be more particularly described in an early warning report to be filed under the Company's SEDAR profile, on August [26], 2020, Dr. Raza Bokhari acquired 805,802 Class B Shares in lieu of cash compensation for his services as Chief Executive Officer and Executive Co-Chairman of the Company. As a result, Dr. Bokhari now beneficially owns, or has control or direction over, in aggregate, approximately 8.5% of the issued and outstanding Class B Shares (on a non-diluted basis). Dr. Bokhari also continues to hold 33.3% of the Company’s outstanding class A multiple voting shares (together with the Class B Shares, the "FSD Shares"). In aggregate, Dr. Bokhari controls approximately 23% of the voting rights attached to the issued and outstanding FSD Shares.
Dr. Bokhari acquired the Class B Shares for investment purposes and has no present intention to sell such securities. Dr. Bokhari is currently prohibited from selling any securities because of lock-up agreements entered into in connection with the recent equity financings by the Company for C$10.125 million on June 9, 2020 and US$10.0 million on August 6, 2020. Depending on market conditions, general economic and industry conditions, trading prices of the Company's securities, the Company's business, financial condition and prospects and/or other relevant factors, Dr. Bokhari may develop such plans or intentions in the future and may from time to time acquire or dispose of securities of the Company.
About FSD Pharma
FSD Pharma Inc. is a publicly-traded holding company, since May 2018.
FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201, by down-regulating the cytokines to effectuate an anti-inflammatory response.
Forward-Looking Statements
Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.
The Company's subject area experts continue to review the scientific evidence/claims/research relevant to the application of PEA and ultramicronized-PEA. The company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
The Phase 2 clinical trial program is subject to a favorable toxicology study and successful completion of ongoing laboratory studies, access to additional financing and review by the FDA of our IND application. The duration and cost of clinical trials can vary significantly depending on multiple factors, including the enrollment rate of patients, country in which trials are conducted, and specific trial protocols required. The process of developing pharmaceutical products and receiving the necessary regulatory approvals for commercialization typically takes several years. Accordingly, no near-term revenues from product sales or services are expected from our ultramicronized-PEA candidate(s). The milestones described above represent customary inflection points for financing by clinical-stage biotech companies. However, there is no assurance that the Company will be able to achieve these clinical milestones, nor, if successful in doing so, that the Company will be able to access additional financing on terms or timing acceptable to the Company.
Certain statements contained in this press release constitute "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws (collectively, "Forward-Looking Information"). Forward-Looking Information includes, but is not limited to, information with respect to FSD Pharma's strategy, plans or future financial or operating performance, receipt of any FDA approvals, including the approval of our IND submission, the completion of any trials regarding the use of FSD201 to treat COVID-19 or whether FSD201 may be effective in treating COVID-19, the costs associated with such planned trials, our ability to obtain required funding and the terms and timing thereof and the ultimate development of any FDA approved synthetic compounds. The use of words such as "budget", "intend", "anticipate", "believe", "expect", "plan", "forecast", "future", "target", "project", "capacity", "could", "should", "focus", "proposed", "scheduled", "outlook", "potential", "estimate" and other similar words, and similar expressions and statements relating to matters that are not historical facts, or statements that certain events or conditions "may" or "will" occur, are intended to identify Forward-Looking Information and are based on FSD Pharma's current beliefs or assumptions as to the outcome and timing of such future events. Such beliefs or assumptions necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such Forward Looking Information. Certain of these risks and uncertainties are described in the Company's continuous disclosure filings available under the Company's SEDAR profile at www.sedar.com and on the Company’s EDGAR profile at www.sec.gov. Forward Looking Information is not a guarantee of performance. The Forward-Looking Information contained in this press release is made as of the date hereof, and FSD Pharma is not obligated to update or revise any Forward-Looking Information, whether as a result of new information, future events or otherwise, except as required by law. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on Forward Looking-Information. The foregoing statements expressly qualify any Forward-Looking Information contained herein.
Good news guys equipment has arrived...
Early Arrival of Equipment from China Slated for Aukam Processing Plant Completion
News Release
Gratomic News out $GRAT / TSX / OTC
Gratomic Announces Engineering Update for Final Layout of its Aukam Graphite Mine Processing Facility
Gratomic Twitter
Electric Vehicle uses nickel graphite I think Gratomic has a good chance to create a supply deal once they finish buildout and start processing the graphite and have material to sell. They use vein graphite which is a healthier alternative to dirty china graphite.
Article on graphite
Follow gratomic here ->>>>> [url]https://twitter.com/GratomicInc
[/url][tag]insert-text-here[/tag]
https://www.bloomberg.com/news/articles/2020-07-22/musk-promises-giant-contract-for-efficiently-mined-nickel
Nickel-coated graphite is manufactured by encapsulating graphite particles with nickel, using a proprietary process developed by Novamet. This process produces a coating of high purity nickel and, most importantly, consistently achieves excellent coverage of the graphite substrate.
I think $GRAT could generate many revenue stream once they have extracted and have the product available for sale.
Watch and see and have faith, some time is needed but tesla is not going away. Neither is their use for graphite as prime material for tesla batteries.
Gratominc $GRAT on a roll today
Graphite is used in tesla batteries
waiting for gratomic to fully complete their processing facility 10% buildout left and then they can start processing the graphite good times coming soon in my opinion.
Brookline Capital Report Giving FSD Pharma $HUGE $11 USD Price Target Great Report for FSD Pharma shareholders that are still holding on
The dawn of the psychedelics industry could not have come at a more needed time for humanity, as global events have served to exacerbate mental health issues related to anxiety and depression. Investors will need help identifying best of breed psychedelics companies and a review of the Red Light Holland story is all you need to know about where the Company is going.
Red Light Holland (TRIP:CSE) is a psychedelics company focused on the development of premium “magic” truffles in the Netherlands. More than just lip service the Company already has these two very strong pillars in place:
TEAM - In order to help guide the company’s development and operations in the psychedelics space, TRIP has signed former Canopy Growth CEO Bruce Linton as chair of its advisory board and Former Canadian Health Minister, Tony Clement, as Senior Advisor. Company President Hans Derix is a native of the Netherlands and an expert in the space with over a decade of accomplished experience.
BUSINESS - The Company's recreational brand of magic truffles are expected to be sold in the Netherlands through existing Smart Shops by mid-September, as well as, its e-commerce platform through microdose packs. To this end, TRIP has already commenced growing its first crop of magic truffles months ahead of schedule. The initial batch of approximately 100,000 grams of magic truffles available in late October, 2020.
As if that wasn't enough, TRIP has also produced a virtual reality experience for prospective customers who want to experience the effects of their products before actually trying it. The AGORACOM thesis of small cap wealth this decade is the convergence of emerging technologies - but even we didn't foresee the explosive intersection of virtual reality and psychedelics!
If you believe in the future of Psychedelics and Psilocybin in particular, then this interview with Todd Shapiro, CEO of Red Light Holland will be a TRIP.
Red Light Holland Engages Radixmotion to Develop an Innovative Virtual Reality Shopping Experience for Dutch Smart Shops and e-Commerce Platforms
News Release
Red Light Holland Engages Former Health Minister, the Honourable, Tony P. Clement, as Senior Advisor to Advisory Board
News Release
Red Light Holland Appoints Bruce Linton as Chairman of Advisory Board
News Release
Red Light Holland Engages Global Comedy Superstar, Russell Peters, to Serve as Chief Creative Officer
News Release
Red Light Holland Commences Magic Truffles Growth Operation in the Netherlands, Months Ahead of Schedule
News Release
Study participants at some of the country's leading medical research centers are going through intense therapy and six-hour psychedelic journeys deep into their minds to do things like quit smoking and worry less.
insert-text-here
The only Psychedelic company that is publically listed that has shown a way to generate revenues by selling magic truffles in the Netherlands.
Watch Todd Shapiro CEO Discuss the plans of the company
Red Light Holland Commences Magic Truffles Growth Operation in the Netherlands, Months Ahead of Schedule
Can't believe Red light Holland does not have a board yet.
Ok so basically Red Light Holland is a magic truffle company listed on CSE.
Todd Shapiro is the CEO
Bruce Linton is an advisor from canopy growth.
Russell Peters the Comedian is on the creative team.
They will be launching their brand in netherlands where it is currently legal to sell magic truffles.
Another place that Gratomic has started to utilize, is a new YouTube page. Here’s a couple informative videos.
Tesla seriously needs clean sources of graphite maybe gratomic can be the ones that deliver this to them in the future?
Gratomic is mining vein graphite which is more environmentally friendly.
China has dirty graphite which is often accompanied by slave labour.
Dirty Chinese Graphite
Tesla has nickel graphtie batteries
tsla graphite nickel
Gratomic is almost completed it's processing facility and will be good to go
sorry posted it 3 times i have a new account didn't realize
Hey guys
Check Out Gratomic $TSLA needs batteries #Graphite
$Grat (#TSX) / $CBULF (#OTC) #cse #stocks
Gratomic Promo Video
#Mining #Metals #Gold #Silver